KR20120025197A - Food composition for improving circulation of blood and manufacturing method thereof - Google Patents
Food composition for improving circulation of blood and manufacturing method thereof Download PDFInfo
- Publication number
- KR20120025197A KR20120025197A KR1020100087432A KR20100087432A KR20120025197A KR 20120025197 A KR20120025197 A KR 20120025197A KR 1020100087432 A KR1020100087432 A KR 1020100087432A KR 20100087432 A KR20100087432 A KR 20100087432A KR 20120025197 A KR20120025197 A KR 20120025197A
- Authority
- KR
- South Korea
- Prior art keywords
- weight
- blood
- blood circulation
- food composition
- rice
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 28
- 238000004519 manufacturing process Methods 0.000 title claims description 5
- 235000013305 food Nutrition 0.000 title abstract description 14
- 210000004369 blood Anatomy 0.000 title description 6
- 239000008280 blood Substances 0.000 title description 6
- 230000004087 circulation Effects 0.000 title description 2
- 230000017531 blood circulation Effects 0.000 claims abstract description 18
- 240000007594 Oryza sativa Species 0.000 claims abstract description 15
- 235000007164 Oryza sativa Nutrition 0.000 claims abstract description 15
- 235000009566 rice Nutrition 0.000 claims abstract description 15
- 235000003261 Artemisia vulgaris Nutrition 0.000 claims abstract description 14
- 235000008331 Pinus X rigitaeda Nutrition 0.000 claims abstract description 14
- 241000018646 Pinus brutia Species 0.000 claims abstract description 14
- 235000011613 Pinus brutia Nutrition 0.000 claims abstract description 14
- 240000001548 Camellia japonica Species 0.000 claims abstract description 13
- 235000018597 common camellia Nutrition 0.000 claims abstract description 12
- GXCLVBGFBYZDAG-UHFFFAOYSA-N N-[2-(1H-indol-3-yl)ethyl]-N-methylprop-2-en-1-amine Chemical compound CN(CCC1=CNC2=C1C=CC=C2)CC=C GXCLVBGFBYZDAG-UHFFFAOYSA-N 0.000 claims abstract description 11
- 240000008620 Fagopyrum esculentum Species 0.000 claims abstract description 10
- 235000009419 Fagopyrum esculentum Nutrition 0.000 claims abstract description 10
- 235000008100 Ginkgo biloba Nutrition 0.000 claims abstract description 10
- 244000194101 Ginkgo biloba Species 0.000 claims abstract description 10
- 235000004426 flaxseed Nutrition 0.000 claims abstract description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 8
- 238000000034 method Methods 0.000 claims abstract description 5
- 238000002156 mixing Methods 0.000 claims abstract description 4
- 235000006679 Mentha X verticillata Nutrition 0.000 claims abstract description 3
- 235000002899 Mentha suaveolens Nutrition 0.000 claims abstract description 3
- 235000001636 Mentha x rotundifolia Nutrition 0.000 claims abstract description 3
- 238000007789 sealing Methods 0.000 claims abstract 2
- 241000202807 Glycyrrhiza Species 0.000 claims description 11
- 235000001453 Glycyrrhiza echinata Nutrition 0.000 claims description 11
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 claims description 11
- 235000017382 Glycyrrhiza lepidota Nutrition 0.000 claims description 11
- 229940010454 licorice Drugs 0.000 claims description 11
- MJYQFWSXKFLTAY-OVEQLNGDSA-N (2r,3r)-2,3-bis[(4-hydroxy-3-methoxyphenyl)methyl]butane-1,4-diol;(2r,3r,4s,5s,6r)-6-(hydroxymethyl)oxane-2,3,4,5-tetrol Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O.C1=C(O)C(OC)=CC(C[C@@H](CO)[C@H](CO)CC=2C=C(OC)C(O)=CC=2)=C1 MJYQFWSXKFLTAY-OVEQLNGDSA-N 0.000 claims description 8
- 235000009051 Ambrosia paniculata var. peruviana Nutrition 0.000 claims description 8
- 235000003097 Artemisia absinthium Nutrition 0.000 claims description 8
- 240000001851 Artemisia dracunculus Species 0.000 claims description 8
- 235000017731 Artemisia dracunculus ssp. dracunculus Nutrition 0.000 claims description 8
- 239000001138 artemisia absinthium Substances 0.000 claims description 8
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 claims description 8
- 238000000855 fermentation Methods 0.000 claims description 7
- 230000004151 fermentation Effects 0.000 claims description 7
- 244000246386 Mentha pulegium Species 0.000 claims description 6
- 235000016257 Mentha pulegium Nutrition 0.000 claims description 6
- 235000004357 Mentha x piperita Nutrition 0.000 claims description 6
- 235000001050 hortel pimenta Nutrition 0.000 claims description 6
- 240000005979 Hordeum vulgare Species 0.000 claims description 5
- 235000007340 Hordeum vulgare Nutrition 0.000 claims description 5
- 230000002269 spontaneous effect Effects 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 19
- 239000004615 ingredient Substances 0.000 abstract description 5
- 239000007788 liquid Substances 0.000 abstract description 2
- 235000003826 Artemisia Nutrition 0.000 abstract 1
- 244000037364 Cinnamomum aromaticum Species 0.000 abstract 1
- 235000014489 Cinnamomum aromaticum Nutrition 0.000 abstract 1
- 244000077995 Coix lacryma jobi Species 0.000 abstract 1
- 235000007354 Coix lacryma jobi Nutrition 0.000 abstract 1
- 235000011201 Ginkgo Nutrition 0.000 abstract 1
- 240000006240 Linum usitatissimum Species 0.000 abstract 1
- 235000004431 Linum usitatissimum Nutrition 0.000 abstract 1
- 244000030166 artemisia Species 0.000 abstract 1
- 235000009052 artemisia Nutrition 0.000 abstract 1
- 238000001914 filtration Methods 0.000 abstract 1
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 18
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 13
- 210000004204 blood vessel Anatomy 0.000 description 12
- 229930003935 flavonoid Natural products 0.000 description 11
- 150000002215 flavonoids Chemical class 0.000 description 11
- 235000017173 flavonoids Nutrition 0.000 description 11
- 239000000126 substance Substances 0.000 description 11
- 230000005764 inhibitory process Effects 0.000 description 10
- 235000012000 cholesterol Nutrition 0.000 description 9
- 208000035475 disorder Diseases 0.000 description 7
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 6
- 206010003210 Arteriosclerosis Diseases 0.000 description 6
- 206010020772 Hypertension Diseases 0.000 description 6
- REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 description 6
- 208000006011 Stroke Diseases 0.000 description 6
- 208000007536 Thrombosis Diseases 0.000 description 6
- 230000003110 anti-inflammatory effect Effects 0.000 description 6
- 235000015097 nutrients Nutrition 0.000 description 6
- 240000006891 Artemisia vulgaris Species 0.000 description 5
- -1 Rhein Chemical compound 0.000 description 5
- 208000011775 arteriosclerosis disease Diseases 0.000 description 5
- 206010012601 diabetes mellitus Diseases 0.000 description 5
- 239000000796 flavoring agent Substances 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 244000005700 microbiome Species 0.000 description 5
- 201000001320 Atherosclerosis Diseases 0.000 description 4
- 208000024172 Cardiovascular disease Diseases 0.000 description 4
- 239000009429 Ginkgo biloba extract Substances 0.000 description 4
- 235000001014 amino acid Nutrition 0.000 description 4
- 150000001413 amino acids Chemical class 0.000 description 4
- 230000008485 antagonism Effects 0.000 description 4
- 208000010668 atopic eczema Diseases 0.000 description 4
- 230000001276 controlling effect Effects 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 201000006549 dyspepsia Diseases 0.000 description 4
- 238000011156 evaluation Methods 0.000 description 4
- 229940068052 ginkgo biloba extract Drugs 0.000 description 4
- 235000020686 ginkgo biloba extract Nutrition 0.000 description 4
- 229930182470 glycoside Natural products 0.000 description 4
- 150000002338 glycosides Chemical class 0.000 description 4
- 208000019622 heart disease Diseases 0.000 description 4
- 210000004185 liver Anatomy 0.000 description 4
- 239000011777 magnesium Substances 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 230000024883 vasodilation Effects 0.000 description 4
- DSSYKIVIOFKYAU-XCBNKYQSSA-N (R)-camphor Chemical compound C1C[C@@]2(C)C(=O)C[C@@H]1C2(C)C DSSYKIVIOFKYAU-XCBNKYQSSA-N 0.000 description 3
- 241000723346 Cinnamomum camphora Species 0.000 description 3
- 201000004624 Dermatitis Diseases 0.000 description 3
- 239000005715 Fructose Substances 0.000 description 3
- 229930091371 Fructose Natural products 0.000 description 3
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 3
- UPYKUZBSLRQECL-UKMVMLAPSA-N Lycopene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1C(=C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=C)CCCC2(C)C UPYKUZBSLRQECL-UKMVMLAPSA-N 0.000 description 3
- 208000008589 Obesity Diseases 0.000 description 3
- ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 description 3
- HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 description 3
- 229930003427 Vitamin E Natural products 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 239000000654 additive Substances 0.000 description 3
- 230000000996 additive effect Effects 0.000 description 3
- 230000000845 anti-microbial effect Effects 0.000 description 3
- 210000001367 artery Anatomy 0.000 description 3
- 201000008937 atopic dermatitis Diseases 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 239000011575 calcium Substances 0.000 description 3
- 229910052791 calcium Inorganic materials 0.000 description 3
- 229960000846 camphor Drugs 0.000 description 3
- 229930008380 camphor Natural products 0.000 description 3
- 150000001746 carotenes Chemical class 0.000 description 3
- 235000005473 carotenes Nutrition 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 239000000284 extract Substances 0.000 description 3
- 235000019634 flavors Nutrition 0.000 description 3
- 235000003599 food sweetener Nutrition 0.000 description 3
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 3
- 238000009499 grossing Methods 0.000 description 3
- 230000001965 increasing effect Effects 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 229910052749 magnesium Inorganic materials 0.000 description 3
- 239000005445 natural material Substances 0.000 description 3
- 235000020824 obesity Nutrition 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 235000018102 proteins Nutrition 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 235000005875 quercetin Nutrition 0.000 description 3
- 229960001285 quercetin Drugs 0.000 description 3
- 230000001953 sensory effect Effects 0.000 description 3
- 239000003765 sweetening agent Substances 0.000 description 3
- 235000019640 taste Nutrition 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 210000003462 vein Anatomy 0.000 description 3
- 229940088594 vitamin Drugs 0.000 description 3
- 229930003231 vitamin Natural products 0.000 description 3
- 235000013343 vitamin Nutrition 0.000 description 3
- 239000011782 vitamin Substances 0.000 description 3
- NCYCYZXNIZJOKI-UHFFFAOYSA-N vitamin A aldehyde Natural products O=CC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C NCYCYZXNIZJOKI-UHFFFAOYSA-N 0.000 description 3
- 235000019165 vitamin E Nutrition 0.000 description 3
- 239000011709 vitamin E Substances 0.000 description 3
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 2
- 208000002874 Acne Vulgaris Diseases 0.000 description 2
- YDQWDHRMZQUTBA-UHFFFAOYSA-N Aloe emodin Chemical compound C1=CC=C2C(=O)C3=CC(CO)=CC(O)=C3C(=O)C2=C1O YDQWDHRMZQUTBA-UHFFFAOYSA-N 0.000 description 2
- 206010003645 Atopy Diseases 0.000 description 2
- 201000006474 Brain Ischemia Diseases 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- 240000004160 Capsicum annuum Species 0.000 description 2
- 235000008534 Capsicum annuum var annuum Nutrition 0.000 description 2
- 235000007862 Capsicum baccatum Nutrition 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 244000201986 Cassia tora Species 0.000 description 2
- 206010008120 Cerebral ischaemia Diseases 0.000 description 2
- 206010010774 Constipation Diseases 0.000 description 2
- 206010012434 Dermatitis allergic Diseases 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 2
- 108010023302 HDL Cholesterol Proteins 0.000 description 2
- 208000031226 Hyperlipidaemia Diseases 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 2
- 239000004472 Lysine Substances 0.000 description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 208000004880 Polyuria Diseases 0.000 description 2
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 2
- 208000003251 Pruritus Diseases 0.000 description 2
- 206010047141 Vasodilatation Diseases 0.000 description 2
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 206010000496 acne Diseases 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000012190 activator Substances 0.000 description 2
- UCTWMZQNUQWSLP-UHFFFAOYSA-N adrenaline Chemical compound CNCC(O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-UHFFFAOYSA-N 0.000 description 2
- 230000002776 aggregation Effects 0.000 description 2
- 238000004220 aggregation Methods 0.000 description 2
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 2
- 229940008102 alloin Drugs 0.000 description 2
- AFHJQYHRLPMKHU-CGISPIQUSA-N aloin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1C1C2=CC(CO)=CC(O)=C2C(=O)C2=C(O)C=CC=C21 AFHJQYHRLPMKHU-CGISPIQUSA-N 0.000 description 2
- 230000001093 anti-cancer Effects 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- RNXZPKOEJUFJON-UHFFFAOYSA-N aurantio-obtusin Chemical compound CC1=C(O)C(OC)=C2C(=O)C3=C(O)C(OC)=C(O)C=C3C(=O)C2=C1 RNXZPKOEJUFJON-UHFFFAOYSA-N 0.000 description 2
- 230000036772 blood pressure Effects 0.000 description 2
- 239000001728 capsicum frutescens Substances 0.000 description 2
- 206010008118 cerebral infarction Diseases 0.000 description 2
- LQGUBLBATBMXHT-UHFFFAOYSA-N chrysophanol Chemical compound C1=CC=C2C(=O)C3=CC(C)=CC(O)=C3C(=O)C2=C1O LQGUBLBATBMXHT-UHFFFAOYSA-N 0.000 description 2
- 210000002808 connective tissue Anatomy 0.000 description 2
- 230000008602 contraction Effects 0.000 description 2
- 239000010949 copper Substances 0.000 description 2
- 208000029078 coronary artery disease Diseases 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 230000035619 diuresis Effects 0.000 description 2
- 239000002934 diuretic Substances 0.000 description 2
- 230000001882 diuretic effect Effects 0.000 description 2
- 230000035622 drinking Effects 0.000 description 2
- 210000004177 elastic tissue Anatomy 0.000 description 2
- 235000020776 essential amino acid Nutrition 0.000 description 2
- 239000003797 essential amino acid Substances 0.000 description 2
- 206010016256 fatigue Diseases 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- 210000000497 foam cell Anatomy 0.000 description 2
- 229940124600 folk medicine Drugs 0.000 description 2
- 235000013922 glutamic acid Nutrition 0.000 description 2
- 239000004220 glutamic acid Substances 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 208000024798 heartburn Diseases 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 230000007803 itching Effects 0.000 description 2
- 206010023332 keratitis Diseases 0.000 description 2
- XMGQYMWWDOXHJM-UHFFFAOYSA-N limonene Chemical compound CC(=C)C1CCC(C)=CC1 XMGQYMWWDOXHJM-UHFFFAOYSA-N 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- 239000011572 manganese Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 239000000401 methanolic extract Substances 0.000 description 2
- 210000001616 monocyte Anatomy 0.000 description 2
- 208000010125 myocardial infarction Diseases 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 235000008390 olive oil Nutrition 0.000 description 2
- 239000004006 olive oil Substances 0.000 description 2
- 210000001328 optic nerve Anatomy 0.000 description 2
- 229940124595 oriental medicine Drugs 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- PKUBGLYEOAJPEG-UHFFFAOYSA-N physcion Natural products C1=C(C)C=C2C(=O)C3=CC(C)=CC(O)=C3C(=O)C2=C1O PKUBGLYEOAJPEG-UHFFFAOYSA-N 0.000 description 2
- FFWOKTFYGVYKIR-UHFFFAOYSA-N physcion Chemical compound C1=C(C)C=C2C(=O)C3=CC(OC)=CC(O)=C3C(=O)C2=C1O FFWOKTFYGVYKIR-UHFFFAOYSA-N 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 208000017520 skin disease Diseases 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 2
- 230000001256 tonic effect Effects 0.000 description 2
- WEHXAEGTVPWKDY-UHFFFAOYSA-N toralactone Chemical compound C1=C(C)OC(=O)C=2C1=CC1=CC(OC)=CC(O)=C1C=2O WEHXAEGTVPWKDY-UHFFFAOYSA-N 0.000 description 2
- 235000019155 vitamin A Nutrition 0.000 description 2
- 239000011719 vitamin A Substances 0.000 description 2
- 229940046009 vitamin E Drugs 0.000 description 2
- 229940045997 vitamin a Drugs 0.000 description 2
- 230000037303 wrinkles Effects 0.000 description 2
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 description 1
- OQWKEEOHDMUXEO-UHFFFAOYSA-N (6)-shogaol Natural products CCCCCC=CC(=O)CCC1=CC=C(O)C(OC)=C1 OQWKEEOHDMUXEO-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- GJJVAFUKOBZPCB-UHFFFAOYSA-N 2-methyl-2-(4,8,12-trimethyltrideca-3,7,11-trienyl)-3,4-dihydrochromen-6-ol Chemical compound OC1=CC=C2OC(CCC=C(C)CCC=C(C)CCC=C(C)C)(C)CCC2=C1 GJJVAFUKOBZPCB-UHFFFAOYSA-N 0.000 description 1
- CFKMVGJGLGKFKI-UHFFFAOYSA-N 4-chloro-m-cresol Chemical compound CC1=CC(O)=CC=C1Cl CFKMVGJGLGKFKI-UHFFFAOYSA-N 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- RSWGJHLUYNHPMX-UHFFFAOYSA-N Abietic-Saeure Natural products C12CCC(C(C)C)=CC2=CCC2C1(C)CCCC2(C)C(O)=O RSWGJHLUYNHPMX-UHFFFAOYSA-N 0.000 description 1
- 206010063409 Acarodermatitis Diseases 0.000 description 1
- 208000000044 Amnesia Diseases 0.000 description 1
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Natural products OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- 231100000699 Bacterial toxin Toxicity 0.000 description 1
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 description 1
- JMGZEFIQIZZSBH-UHFFFAOYSA-N Bioquercetin Natural products CC1OC(OCC(O)C2OC(OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5)C(O)C2O)C(O)C(O)C1O JMGZEFIQIZZSBH-UHFFFAOYSA-N 0.000 description 1
- 201000004569 Blindness Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 235000006467 Camellia japonica Nutrition 0.000 description 1
- 235000014552 Cassia tora Nutrition 0.000 description 1
- VWDXGKUTGQJJHJ-UHFFFAOYSA-N Catenarin Natural products C1=C(O)C=C2C(=O)C3=C(O)C(C)=CC(O)=C3C(=O)C2=C1O VWDXGKUTGQJJHJ-UHFFFAOYSA-N 0.000 description 1
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 1
- 208000001840 Dandruff Diseases 0.000 description 1
- 206010012289 Dementia Diseases 0.000 description 1
- 206010012438 Dermatitis atopic Diseases 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 239000010282 Emodin Substances 0.000 description 1
- RBLJKYCRSCQLRP-UHFFFAOYSA-N Emodin-dianthron Natural products O=C1C2=CC(C)=CC(O)=C2C(=O)C2=C1CC(=O)C=C2O RBLJKYCRSCQLRP-UHFFFAOYSA-N 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 206010014970 Ephelides Diseases 0.000 description 1
- 206010015150 Erythema Diseases 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 239000001116 FEMA 4028 Substances 0.000 description 1
- 206010016228 Fasciitis Diseases 0.000 description 1
- 206010016952 Food poisoning Diseases 0.000 description 1
- 208000019331 Foodborne disease Diseases 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 235000000554 Glycyrrhiza uralensis Nutrition 0.000 description 1
- 240000008917 Glycyrrhiza uralensis Species 0.000 description 1
- 239000004378 Glycyrrhizin Substances 0.000 description 1
- YOOXNSPYGCZLAX-UHFFFAOYSA-N Helminthosporin Natural products C1=CC(O)=C2C(=O)C3=CC(C)=CC(O)=C3C(=O)C2=C1O YOOXNSPYGCZLAX-UHFFFAOYSA-N 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 108010016183 Human immunodeficiency virus 1 p16 protease Proteins 0.000 description 1
- 206010020565 Hyperaemia Diseases 0.000 description 1
- 206010020710 Hyperphagia Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- IMQLKJBTEOYOSI-GPIVLXJGSA-N Inositol-hexakisphosphate Chemical compound OP(O)(=O)O[C@H]1[C@H](OP(O)(O)=O)[C@@H](OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@@H]1OP(O)(O)=O IMQLKJBTEOYOSI-GPIVLXJGSA-N 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- UGNZSMZSJYOGNX-UHFFFAOYSA-N Isoviocristine Natural products O=C1C=C(C)C(=O)C2=CC3=CC(OC)=CC(O)=C3C(O)=C21 UGNZSMZSJYOGNX-UHFFFAOYSA-N 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 241000207923 Lamiaceae Species 0.000 description 1
- 206010024264 Lethargy Diseases 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- PWHULOQIROXLJO-UHFFFAOYSA-N Manganese Chemical compound [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 description 1
- 208000003351 Melanosis Diseases 0.000 description 1
- 208000026139 Memory disease Diseases 0.000 description 1
- 235000016278 Mentha canadensis Nutrition 0.000 description 1
- 244000245214 Mentha canadensis Species 0.000 description 1
- 208000001140 Night Blindness Diseases 0.000 description 1
- CFLNHFUPWNRWJA-UHFFFAOYSA-N Obtusin Chemical compound O=C1C2=CC(C)=C(O)C(OC)=C2C(=O)C2=C1C=C(OC)C(OC)=C2O CFLNHFUPWNRWJA-UHFFFAOYSA-N 0.000 description 1
- OBBJQZSMXOJMCN-UHFFFAOYSA-N Obtusin Natural products COc1cc2C=CC(=O)Oc2c3OCC(Oc13)C(=C)C OBBJQZSMXOJMCN-UHFFFAOYSA-N 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 208000018262 Peripheral vascular disease Diseases 0.000 description 1
- 206010057249 Phagocytosis Diseases 0.000 description 1
- IMQLKJBTEOYOSI-UHFFFAOYSA-N Phytic acid Natural products OP(O)(=O)OC1C(OP(O)(O)=O)C(OP(O)(O)=O)C(OP(O)(O)=O)C(OP(O)(O)=O)C1OP(O)(O)=O IMQLKJBTEOYOSI-UHFFFAOYSA-N 0.000 description 1
- 235000008578 Pinus strobus Nutrition 0.000 description 1
- 240000007320 Pinus strobus Species 0.000 description 1
- 208000004403 Prostatic Hyperplasia Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 244000088415 Raphanus sativus Species 0.000 description 1
- 235000006140 Raphanus sativus var sativus Nutrition 0.000 description 1
- NTGIIKCGBNGQAR-UHFFFAOYSA-N Rheoemodin Natural products C1=C(O)C=C2C(=O)C3=CC(O)=CC(O)=C3C(=O)C2=C1O NTGIIKCGBNGQAR-UHFFFAOYSA-N 0.000 description 1
- KHPCPRHQVVSZAH-HUOMCSJISA-N Rosin Natural products O(C/C=C/c1ccccc1)[C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 KHPCPRHQVVSZAH-HUOMCSJISA-N 0.000 description 1
- 241000447727 Scabies Species 0.000 description 1
- 208000034189 Sclerosis Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 239000004376 Sucralose Substances 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 241001122767 Theaceae Species 0.000 description 1
- BIJOPUWEMBBDEG-UHFFFAOYSA-N Torachrysone Natural products OC1=C(C(C)=O)C(C)=CC2=CC(OC)=CC(O)=C21 BIJOPUWEMBBDEG-UHFFFAOYSA-N 0.000 description 1
- 240000001717 Vaccinium macrocarpon Species 0.000 description 1
- 235000012545 Vaccinium macrocarpon Nutrition 0.000 description 1
- 235000002118 Vaccinium oxycoccus Nutrition 0.000 description 1
- 229930003270 Vitamin B Natural products 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- OQWKEEOHDMUXEO-BQYQJAHWSA-N [6]-Shogaol Chemical compound CCCCC\C=C\C(=O)CCC1=CC=C(O)C(OC)=C1 OQWKEEOHDMUXEO-BQYQJAHWSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 1
- 229960004373 acetylcholine Drugs 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- OENHQHLEOONYIE-UKMVMLAPSA-N all-trans beta-carotene Natural products CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C OENHQHLEOONYIE-UKMVMLAPSA-N 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- WLXGUTUUWXVZNM-UHFFFAOYSA-N anthraglycoside A Natural products C1=C(C)C=C2C(=O)C3=CC(OC)=CC(O)=C3C(=O)C2=C1OC1OC(CO)C(O)C(O)C1O WLXGUTUUWXVZNM-UHFFFAOYSA-N 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 230000003266 anti-allergic effect Effects 0.000 description 1
- 230000001760 anti-analgesic effect Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000001754 anti-pyretic effect Effects 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 210000000702 aorta abdominal Anatomy 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 239000000688 bacterial toxin Substances 0.000 description 1
- 230000003796 beauty Effects 0.000 description 1
- 235000013405 beer Nutrition 0.000 description 1
- 235000021028 berry Nutrition 0.000 description 1
- 235000013734 beta-carotene Nutrition 0.000 description 1
- TUPZEYHYWIEDIH-WAIFQNFQSA-N beta-carotene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2=CCCCC2(C)C TUPZEYHYWIEDIH-WAIFQNFQSA-N 0.000 description 1
- 239000011648 beta-carotene Substances 0.000 description 1
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 description 1
- 235000011175 beta-cyclodextrine Nutrition 0.000 description 1
- 229960002747 betacarotene Drugs 0.000 description 1
- 229960004853 betadex Drugs 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 235000019658 bitter taste Nutrition 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 210000004958 brain cell Anatomy 0.000 description 1
- 239000010495 camellia oil Substances 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 235000013339 cereals Nutrition 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000013522 chelant Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- NZPQWZZXRKZCDU-UHFFFAOYSA-N chrysophanol Natural products Cc1cc(O)c2C(=O)c3c(O)cccc3Oc2c1 NZPQWZZXRKZCDU-UHFFFAOYSA-N 0.000 description 1
- 239000005515 coenzyme Substances 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 235000004634 cranberry Nutrition 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 238000001784 detoxification Methods 0.000 description 1
- 235000013325 dietary fiber Nutrition 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 206010013663 drug dependence Diseases 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- RHMXXJGYXNZAPX-UHFFFAOYSA-N emodin Chemical compound C1=C(O)C=C2C(=O)C3=CC(C)=CC(O)=C3C(=O)C2=C1O RHMXXJGYXNZAPX-UHFFFAOYSA-N 0.000 description 1
- VASFLQKDXBAWEL-UHFFFAOYSA-N emodin Natural products OC1=C(OC2=C(C=CC(=C2C1=O)O)O)C1=CC=C(C=C1)O VASFLQKDXBAWEL-UHFFFAOYSA-N 0.000 description 1
- 210000003372 endocrine gland Anatomy 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 208000001780 epistaxis Diseases 0.000 description 1
- IVTMALDHFAHOGL-UHFFFAOYSA-N eriodictyol 7-O-rutinoside Natural products OC1C(O)C(O)C(C)OC1OCC1C(O)C(O)C(O)C(OC=2C=C3C(C(C(O)=C(O3)C=3C=C(O)C(O)=CC=3)=O)=C(O)C=2)O1 IVTMALDHFAHOGL-UHFFFAOYSA-N 0.000 description 1
- 231100000321 erythema Toxicity 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 235000004626 essential fatty acids Nutrition 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000004438 eyesight Effects 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 239000011888 foil Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 235000015203 fruit juice Nutrition 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 244000053095 fungal pathogen Species 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 230000035784 germination Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 1
- 229960004949 glycyrrhizic acid Drugs 0.000 description 1
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 1
- 235000019410 glycyrrhizin Nutrition 0.000 description 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 229910001385 heavy metal Inorganic materials 0.000 description 1
- 230000011132 hemopoiesis Effects 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 230000002439 hemostatic effect Effects 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 235000012907 honey Nutrition 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 229930013686 lignan Natural products 0.000 description 1
- 235000009408 lignans Nutrition 0.000 description 1
- 150000005692 lignans Chemical class 0.000 description 1
- 229940087305 limonene Drugs 0.000 description 1
- 235000001510 limonene Nutrition 0.000 description 1
- 235000020778 linoleic acid Nutrition 0.000 description 1
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 description 1
- 230000029226 lipidation Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 229910052748 manganese Inorganic materials 0.000 description 1
- 230000007721 medicinal effect Effects 0.000 description 1
- 230000006984 memory degeneration Effects 0.000 description 1
- 208000023060 memory loss Diseases 0.000 description 1
- 229940041616 menthol Drugs 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 230000027939 micturition Effects 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000007383 nerve stimulation Effects 0.000 description 1
- 208000004296 neuralgia Diseases 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 235000020660 omega-3 fatty acid Nutrition 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 235000020830 overeating Nutrition 0.000 description 1
- 230000016087 ovulation Effects 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 235000019161 pantothenic acid Nutrition 0.000 description 1
- 239000011713 pantothenic acid Substances 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 235000020737 peppermint extract Nutrition 0.000 description 1
- 230000008782 phagocytosis Effects 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 239000000467 phytic acid Substances 0.000 description 1
- 235000002949 phytic acid Nutrition 0.000 description 1
- 229940068041 phytic acid Drugs 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- FDRQPMVGJOQVTL-UHFFFAOYSA-N quercetin rutinoside Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 FDRQPMVGJOQVTL-UHFFFAOYSA-N 0.000 description 1
- 235000021067 refined food Nutrition 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000003716 rejuvenation Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- ALABRVAAKCSLSC-UHFFFAOYSA-N rutin Natural products CC1OC(OCC2OC(O)C(O)C(O)C2O)C(O)C(O)C1OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5 ALABRVAAKCSLSC-UHFFFAOYSA-N 0.000 description 1
- IKGXIBQEEMLURG-BKUODXTLSA-N rutin Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@@H]1OC[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 IKGXIBQEEMLURG-BKUODXTLSA-N 0.000 description 1
- 235000005493 rutin Nutrition 0.000 description 1
- 229960004555 rutoside Drugs 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 235000017709 saponins Nutrition 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 208000005687 scabies Diseases 0.000 description 1
- 210000004761 scalp Anatomy 0.000 description 1
- 210000002374 sebum Anatomy 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000037307 sensitive skin Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 230000005808 skin problem Effects 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 238000012453 sprague-dawley rat model Methods 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 238000010025 steaming Methods 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 208000023516 stroke disease Diseases 0.000 description 1
- 208000011117 substance-related disease Diseases 0.000 description 1
- 235000019408 sucralose Nutrition 0.000 description 1
- BAQAVOSOZGMPRM-QBMZZYIRSA-N sucralose Chemical compound O[C@@H]1[C@@H](O)[C@@H](Cl)[C@@H](CO)O[C@@H]1O[C@@]1(CCl)[C@@H](O)[C@H](O)[C@@H](CCl)O1 BAQAVOSOZGMPRM-QBMZZYIRSA-N 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 235000018553 tannin Nutrition 0.000 description 1
- 239000001648 tannin Substances 0.000 description 1
- 229920001864 tannin Polymers 0.000 description 1
- 229960003080 taurine Drugs 0.000 description 1
- JBQYATWDVHIOAR-UHFFFAOYSA-N tellanylidenegermanium Chemical compound [Te]=[Ge] JBQYATWDVHIOAR-UHFFFAOYSA-N 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- 229930003799 tocopherol Natural products 0.000 description 1
- 239000011732 tocopherol Substances 0.000 description 1
- 229960001295 tocopherol Drugs 0.000 description 1
- 235000010384 tocopherol Nutrition 0.000 description 1
- 229930003802 tocotrienol Natural products 0.000 description 1
- 239000011731 tocotrienol Substances 0.000 description 1
- 235000019148 tocotrienols Nutrition 0.000 description 1
- KHPCPRHQVVSZAH-UHFFFAOYSA-N trans-cinnamyl beta-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OCC=CC1=CC=CC=C1 KHPCPRHQVVSZAH-UHFFFAOYSA-N 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- 150000003648 triterpenes Chemical class 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 208000019553 vascular disease Diseases 0.000 description 1
- 210000003556 vascular endothelial cell Anatomy 0.000 description 1
- 230000025033 vasoconstriction Effects 0.000 description 1
- 235000019156 vitamin B Nutrition 0.000 description 1
- 239000011720 vitamin B Substances 0.000 description 1
- 235000010374 vitamin B1 Nutrition 0.000 description 1
- 239000011691 vitamin B1 Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- QYSXJUFSXHHAJI-YRZJJWOYSA-N vitamin D3 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-YRZJJWOYSA-N 0.000 description 1
- 235000005282 vitamin D3 Nutrition 0.000 description 1
- 239000011647 vitamin D3 Substances 0.000 description 1
- 229940021056 vitamin d3 Drugs 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 235000015041 whisky Nutrition 0.000 description 1
- 230000002087 whitening effect Effects 0.000 description 1
- 239000002023 wood Substances 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1
- OENHQHLEOONYIE-JLTXGRSLSA-N β-Carotene Chemical compound CC=1CCCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-JLTXGRSLSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/3262—Foods, ingredients or supplements having a functional effect on health having an effect on blood cholesterol
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Mycology (AREA)
- Health & Medical Sciences (AREA)
- Nutrition Science (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Description
본 발명은 천연 성분을 포함하는 혈액순환 개선용 식품 조성물에 관한 것으로, 더욱 상세하게는 아마씨, 메밀, 약쑥, 은행잎, 솔잎, 결명자, 감초, 박하, 엿기름, 쌀, 율무, 동백, 흑설탕 및 알콜을 포함하는 혈액순환 개선용 식품 조성물에 관한 것이다. The present invention relates to a food composition for improving blood circulation comprising natural ingredients, and more specifically, flaxseed, buckwheat, wormwood, ginkgo biloba, pine needles, crystallizer, licorice, peppermint, malt, rice, barley, camellia, brown sugar and alcohol. It relates to a food composition for improving blood circulation comprising.
혈액순환 (the circulation of blood)이란 혈액이 심장을 중심으로 혈관을 따라 우리의 신체를 순환하는 것으로 산소를 신체 각 조직에 공급하고 탄산가스를 방출하고, 영양소를 보급하고 대사 산물을 방출하며, 여러 내분비선에서 호르몬을 운반하여 특정기관의 기능을 조절하며 그밖에 병원균 조절작용과 체온조절, 삼투압조절, 수분조절 등의 기능을 수행하는 과정이다. 혈관은 동백, 모세혈관, 정맥으로 구성되어 있다. 동맥은 외탄력선판과 결합조직으로 되어 있는 외막, 평활근이 많고 그 안에 다수의 탄력섬유를 함유하고 있는 중막, 제일 안쪽의 내피세포와 그것을 둘러싸고 있는 결합조직과 탄력섬유가 모여서 내강성판으로 되어 있는 내막으로 이루어져 있다. 모세혈관은 소동맥과 소정맥이 연결된 것으로 그물모양으로 가늘게 가지가 나 있으며 직경 0.008?0.02mm의 가는 관으로서 적혈구가 1?2줄로 통과될 정도이고 육안으로는 보이지 않으며, 이 모세혈관을 통해서 혈액 중의 산소와 영양분은 조직내로 보내지고 조직에서 만들어진 CO2나 노폐물은 혈관으로 들어온다. 정맥의 외막은 비교적 두껍고 내막과 중막은 얇으며 압력이 없고 다른 혈관에 비해 혈류가 약하여 심장보다 낮은 부분의 정맥에서 역류할 위험성이 있기 때문에 역류 방지용 판막(valve)이 붙어 있다.The circulation of blood circulates our bodies along the blood vessels around the heart, supplying oxygen to the tissues of the body, releasing carbon dioxide, nutrients, and metabolites. The endocrine gland carries hormones to regulate the function of specific organs, and to carry out other functions such as controlling pathogens, controlling body temperature, controlling osmotic pressure, and controlling water. Blood vessels consist of camellia, capillaries and veins. Arteries are the outer membrane consisting of external elastic sun board and connective tissue, the mesothelial membrane with a lot of smooth muscles, containing a number of elastic fibers, the innermost endothelial cells, and the connective tissue and elastic fibers surrounding them. Consists of Capillary vessels are small arteries and small veins that are thinly branched in the shape of a net, 0.008 to 0.02 mm in diameter, and have red blood cells passing through 1-2 lines and are invisible to the naked eye. And nutrients are sent into the tissue and the CO 2 and waste products produced by the tissue enter the blood vessels. The vein's outer membrane is relatively thick, the inner and middle membranes are thin, there is no pressure, and the blood flow is weak compared to other blood vessels.
혈액순환 장애란 우리 온몸의 구석구석에 뻗어 있는 혈관이 탄력을 잃고 내벽에 콜레스테롤 등이 침착되어 혈관 내강이 좁아져 혈액 순환이 원활이 이루어지지 못하는 것을 말한다. 혈액순환 장애는 손발 차고 저림, 뒷목 당김, 어깨 결림, 기억력 감퇴, 무기력, 집중력 약화, 현기증 및 만성 피로 증상을 유발하여 정상적인 생활을 영위하는데 어려움이 많게 된다. Blood circulation disorder refers to the loss of elasticity of blood vessels extending in every corner of our body and the deposition of cholesterol on the inner wall, narrowing the lumen of the blood vessels, resulting in poor blood circulation. Blood circulation disorders cause difficulty in living a normal life by causing colds and feet, pulling back, stiff shoulders, memory loss, lethargy, weakness, dizziness and chronic fatigue.
혈액순환에 장애가 생겨 발생하는 심혈관계 질환으로 고혈압, 동맥경화증, 심장병, 뇌졸중 등은 오늘날 성인병의 주종을 이루고 있으며 사망률이 높은 질병으로 70세까지는 암에 의한 사망률이 가장 높으나 70세 이후에는 심혈관계질환이 제 1의 사망원인이다. 이러한 심혈관계 질환은 서로 밀접한 관련이 있는데, 급속한 경제의 발전, 식생활의 발전, 사회 환경의 변화와 서구화로 질병양상이 서구화되어 가면서 증가하고 있으며, 총 칼로리 섭취 증가와 지방섭취 증가로 콜레스테롤을 비롯하여 혈중 지질치의 현저한 상승을 초래하여 관상동맥질환, 뇌졸중, 말초혈관질환과 같은 동맥경화성 심혈관 질환 발생도 현저히 증가하고 있다. 고지혈증, 동맥경화증, 심근경색증 및 뇌혈전증 등 심혈관계 질환의 발생원인은 높은 지방함량과 식이섬유 함량이 적은 가공식품의 섭취, 유전적인 요인, 흡연, 음주, 고혈압, 당뇨, 비만, 운동부족, 과도한 스트레스 등이 관여한다고 널리 알려져 있으며, 이러한 심혈관계 질환을 일으키는 기본적인 병변은 동맥경화증으로 그 원인에 대한 역학적 및 실험적 연구로 다양한 위험인자를 밝혀내고 있다. 이러한 병변의 발생과정을 살펴보면, 물리적 또는 화학적인 상처는 혈관의 단층세포표면에 손상을 야기하고, 혈관벽에 혈전 생성을 유도할 수 있는 혈전 부착 수용체가 발현되고, 여기에 단구(monocyte), T-임파구(T-lympocyte) 및 혈소판 등이 부착하여, 혈관 내막세포 사이를 통하여 혈관벽 속으로 침윤하게 되는데, 이때, 혈액 속의 지질단백질도 함께 유입된다. 혈관벽 내부로 유입된 단구들은 지질 단백질을 탐식하여 대식세포(macrophage)로 변형되고, 대식세포들은 콜레스테롤을 축적하여 포말세포(form cells)를 형성한다. 포말세포들은 염증반응과 세포성장을 반복하면서 혈관벽을 파괴하거나 비후하여, 혈액중의 혈소판이 점착됨으로 혈전을 형성하게 한다. 이러한 진행과정은 결국, 동맥경화에 의한 혈관의 협착과 혈전에 의한 혈관의 완전 폐쇠로 심장으로의 혈액공급이 순간적으로 차단되어, 심근경색에 의한 사망을 유도한다.High blood pressure, arteriosclerosis, heart disease, and stroke are the main causes of adult disease today. High mortality is the highest mortality caused by cancer until 70 years old, but cardiovascular disease after 70 years. This is the first cause of death. These cardiovascular diseases are closely related to each other. The rapid development of the economy, the development of diet, the change of the social environment, and the westernization of the disease pattern are increasing as Westernization increases. It leads to a marked rise in lipid levels, and the incidence of atherosclerotic cardiovascular diseases such as coronary artery disease, stroke, and peripheral vascular disease is also significantly increased. The causes of cardiovascular diseases such as hyperlipidemia, arteriosclerosis, myocardial infarction and thrombosis are caused by the consumption of processed foods with high fat content and low dietary fiber content, genetic factors, smoking, drinking, high blood pressure, diabetes, obesity, lack of exercise and excessive stress. It is widely known that the incidence of such cardiovascular diseases is atherosclerosis, and epidemiological and experimental studies of the causes have revealed various risk factors. Looking at the development of these lesions, physical or chemical wounds cause damage to the surface of the monolayer cell of blood vessels, and thrombosis receptors are expressed on the walls of the blood vessels, whereby monocyte, T- Lymphocytes (T-lympocyte) and platelets are attached and infiltrate into the vascular wall through the vascular endothelial cells, at this time, lipoproteins in the blood are also introduced. The monocytes introduced into the blood vessel wall are converted to macrophage by phagocytosis of lipid proteins, and macrophages accumulate cholesterol to form foam cells. The foam cells break down or thicken the blood vessel wall, repeating the inflammatory response and cell growth, causing platelets in the blood to adhere to form thrombus. This progression eventually results in a blockage of blood supply to the heart due to narrowing of blood vessels due to atherosclerosis and complete closure of blood vessels by thrombus, leading to death due to myocardial infarction.
아마씨에는 단백질과 오메가-3 및 오메가-6와 같은 필수지방산과 리그난(lignan, 항암물질)과 같이 다른 씨앗에서 발견할 수 없는 항암물질 및 관상동맥, 심장질환과 같은 만성질환의 발병을 감소시켜주는 물질이 다량 함유되어 있으며, 그 효능으로는 각종 혈관 및 심장질환예방, 뇌졸증의 예방 및 치료, 항암효과, 아토피성 피부염 등의 피부질환 및 두뇌의 성장 발육촉진 등이 있다.Flaxseed reduces the incidence of proteins and essential fatty acids such as omega-3 and omega-6 and other cancers not found in other seeds such as lignans and chronic diseases such as coronary and heart disease. It contains a large amount of substance, and its effects include prevention of various blood vessels and heart diseases, prevention and treatment of stroke, anticancer effect, skin diseases such as atopic dermatitis, and promotion of brain growth.
메밀은 단백질 함량이 높을 뿐만 아니라 필수 아미노산인 라이신(lysine)의 함량이 다른 곡류에 비하여 월등히 높고 아연(Zn), 마그네슘(Mg), 망간(Mn) 및 구리(Cu)를 풍부하게 함유하고 있다. 특히 메밀에 함유된 플라보노이드(flavonoid)계 물질인 루틴(rutin)은 당뇨병, 비만, 각종 혈관계의 질환 및 치근막염의 예방과 치료에 효능이 있으며, 쿼세틴(quercetin)을 비롯한 각종 페놀성 물질은 천연의 항산화제는 물론 각종 의약품의 원료로서 유용하다.Buckwheat not only has a high protein content but also has a high content of essential amino acid lysine (lysine) and is rich in zinc (Zn), magnesium (Mg), manganese (Mn) and copper (Cu). In particular, rutin, a flavonoid-based substance contained in buckwheat, is effective in preventing and treating diabetes mellitus, obesity, various vascular diseases, and fasciitis, and various phenolic substances including quercetin are natural. Antioxidants are of course useful as raw materials for various pharmaceuticals.
약쑥은 동의보감, 본초강목 및 최근의 문헌에서 보면 항균, 소염 살균, 지혈조경, 보혈기능 등의 작용으로부터 나오는 독특한 약효가 있어 피부의 보습효과와 모세혈관을 튼튼히 하는 유효성분으로 피부의 염증을 진정시키며, 재생을 촉진하는 역할과 피부의 미백효과 피부병- 습진, 여드름, 기미, 민감성피부-치료, 지혈제로써 코피 날 때나 칼에 베었을 때 지혈, 여성의 냉증, 부인의 하혈, 이뇨, 해열 작용 등에 효과가 있는 것으로 알려져 있어 한방에서 뜸이나 찜질, 쑥차, 쑥즙, 쑥주 등 음료화와 쑥탕, 쑥 사우나 등 건강 측면에서 우리 민족의 오랜 사랑을 받아 온 내복 뿐 만 아니라 외용치료로 사용되고 있는 인체에 매우 유용한 식물이다. 이러한 성질을 이용하여 많은 특허 기술들이 보고되고 있다.The wormwood has a unique medicinal effect derived from the effect of antimicrobial, anti-inflammatory, anti-inflammatory sterilization, hemostatic landscaping, and hematopoiesis in the recent literature, soothing the skin's inflammation with an active ingredient that strengthens the skin and strengthens capillaries. , Skin rejuvenation effect and skin whitening effect-eczema, acne, blemish, sensitive skin-treatment, hemostasis when nosebleed or cut into knife, coldness in women, bleeding in women, diuresis, antipyretic effect It is known that there are moxibustion, steaming, mugwort tea, mugwort juice, mugwort, etc. in oriental medicine, and it is very useful for human body which is used for external treatment as well as underwear that has long been loved by our people in health such as mugwort, mugwort sauna, etc. to be. Many patent technologies have been reported using this property.
은행잎추출물은 기능물질인 후라보노이드로서 은행잎추출중의 후라보노이드는 대부분이 배당체로 존재하고 있다. 이것들의 주요한 물질은 캠페놀과 케세르세틴 등으로 되어 있는 배당체이다.Ginkgo biloba extract is a functional substance flavonoid. Most of the flavonoids in ginkgo biloba extract exist as glycosides. These major substances are glycosides consisting of camphor and quercetin.
현재까지 알려져 있는 은행잎 후라보노이드의 기능은 말초혈관의 확장작용, 관혈관확장작용, 진경작용, SOD 작용등이 있고 또하나의 기능성분으로서 후라보노이드이상으로 중요한 것으로는 테르펜락톤이 있는데 이것의 주요한 기능은 혈소판응집의 저해, 혈전형성의 저해, 혈소판활성인자 (PAF)에 의한 기관지수축작용의 저해 (천식관련)와 염증성질환 및 알레르기성피부염질환에 대한 길항작용, 면역성각막염에 대한 길항작용 PAF에 의한 대뇌혈류량 장해의 저해, 대뇌허혈의 저해등이다.The functions of ginkgo biloba flavonoids known to date are peripheral vasodilation, vasodilatation, myrrhosis, SOD effect, and another functional ingredient is terpenlactone, which is more important than flavonoids. Inhibition of aggregation, inhibition of thrombus formation, inhibition of bronchial contraction by platelet activator (PAF) and antagonism of inflammatory and allergic dermatitis diseases, antagonism of immune keratitis It is the inhibition of disorder and the inhibition of cerebral ischemia.
은행잎추출물은 기능물질인 후라보노이드로서 은행잎추출중의 후라보노이드는 대부분이 배당체로 존재하고 있다. 이것들의 주요한 물질은 캠페놀과 케세르세틴 등으로 되어 있는 배당체이다. 현재까지 알려져 있는 은행잎 후라보노이드의 기능은 말초혈관의 확장작용, 관혈관확장작용, 진경작용, SOD 작용등이 있고 또하나의 기능성분으로서 후라보노이드이상으로 중요한 것으로는 테르펜락톤이 있는데 이것의 주요한 기능은 혈소판응집의 저해, 혈전형성의 저해, 혈소판활성인자 (PAF)에 의한 기관지수축작용의 저해 (천식관련)와 염증성질환 및 알레르기성피부염질환에 대한 길항작용, 면역성각막염에 대한 길항작용 PAF에 의한 대뇌혈류량 장해의 저해, 대뇌허혈의 저해등이다.Ginkgo biloba extract is a functional substance flavonoid. Most of the flavonoids in ginkgo biloba extract exist as glycosides. These major substances are glycosides consisting of camphor and quercetin. The functions of ginkgo biloba flavonoids known to date are peripheral vasodilation, vasodilatation, myrrhosis, SOD effect, and another functional ingredient is terpenlactone, which is more important than flavonoids. Inhibition of aggregation, inhibition of thrombus formation, inhibition of bronchial contraction by platelet activator (PAF) and antagonism of inflammatory and allergic dermatitis diseases, antagonism of immune keratitis It is the inhibition of disorder and the inhibition of cerebral ischemia.
소나무의 잎, 열매, 송진 등은 옛부터 성인병의 예방 또는 치료에 사용되어 왔다. 동의보감에 의하면 솔잎은 위장병, 고혈압, 중풍, 신경통, 천식 등에 효과가 있다고 되어 있으며 민속요법에서도 솔잎을 달인 물이나 솔잎즙, 또는 솔잎을 벌꿀에 담근것이 감기, 고혈압, 동맥경화, 중풍등의 약으로 사용된다. 또한 스트로브 소나무(Pinus strobus)의 솔잎 추출물은 진해시럽의 원료로 사용되고 있다.Pine leaves, berries and rosin have long been used to prevent or treat adult diseases. According to the agreement, pine needles are effective in gastrointestinal diseases, high blood pressure, stroke, neuralgia, asthma, and folk medicine is also used in folk medicine, such as cold, high blood pressure, arteriosclerosis, and stroke. Used. In addition, pine needle extract of Pinus strobus is used as a raw material of Jinhae syrup.
솔잎에는 여러가지 정유성분, 비타민류, 탄닌, 고미성 물질, 플라보노이드, 항균성 물질 등이 있어 이것들이 약리작용을 나타내어지는 것으로 알려졌다. 특히 근래에 와서 이들의 연구에 다르면(한국생물 공학회지 제6권 제1호 55-61쪽,1991년) 솔잎의 메탄올 추출물이 인체내에서 콜레스테롤 합성의 과정에 관계되는 중요한 효소인 3-히드록시-3-메틸 글루타릴 코엔지임 에이 환원요소(3-hydoxy-3-methyl glutaryl coenzyme A raductase)의 활성을 저해하는 것으로 나타나 솔잎을 복용할 경우, 체내의 콜레스테롤 양을 줄일 수 있어 고지혈증, 동맥경화증에 효과가 있다는 것이 증명되었다.Pine needles contain various essential oils, vitamins, tannins, high-flavor substances, flavonoids, and antimicrobial substances, which are known to exhibit pharmacological action. In particular, in recent years, according to their research (Korean Journal of Biotechnology and Bioengineering, Vol. 6, No. 1, pages 55-61, 1991), methanol extract of pine needles is an important enzyme involved in the process of cholesterol synthesis in humans. It has been shown to inhibit the activity of 3-hydoxy-3-methyl glutaryl coenzyme araductase, and taking pine needles can reduce the amount of cholesterol in the body, resulting in hyperlipidemia and arteries. It has been proven effective in sclerosis.
결명자(학명:Cassia tora L.)는 콩과에 속하는 1년생 초본인 초결명의성숙한 종자로서 눈을 밝게한다는 의미에서 결명자라 알려져 있다. 종래에 알려진 결명자중의 약리성분으로는 비타민 A의 전구체인 카로텐(Carotene), 알로애향과 쓴 맛을 내는 알로인(Alloin), 레인(Rhein), 에모딘(Emodin), 크리소판올(Chrysophanol), 알로에-에모딘(Aloe-emodin), 피션(Physcion), 오브튜신(Obtusin), 아우란티오-오브튜신(Aurantio-obtusin), 루브로퓨사린(Rubrofusrin), 토라크리손(Torachryson),토라락톤(Toralactone) 등이 있다. 이들 성분들중 카로텐 등은 시신경자극과 전달에 필수성분으로 시력 유지에 유효할 뿐 아니라, 적안(충혈), 청맹(시신경위축), 작목(야맹증) 등에도 유효하고, 알로인은 혈중의 콜레스테롤 함량을 낮추어줌은 물론 혈압강하에도 유효하다. 이외에도, 결명자는 간과 콩팥의 이뇨작용을 도와주며 장의 열을 내려 변비를 예방 치료하는 효과가 있다.Cassia tora L. is a mature seed of a superdetermination, a herbaceous herb that is a year-old herb. Among the known pharmacological components, carotene (Carotene), a precursor of vitamin A, alloin and bitter taste Alloin, Rhein, Emodin, Chrypananol (Chrysophanol) , Aloe-emodin, Physcion, Obtusin, Aurantio-obtusin, Rubrofusrin, Torachryson, Tora Lactones (Toralactone) and the like. Among these components, carotene is an essential ingredient for optic nerve stimulation and delivery, and is effective not only for maintaining eyesight, but also for red eyes (hyperemia), blue blindness (optic nerve atrophy), and cropping (night blindness). Lowers blood pressure is also effective. In addition, the deficiency helps the liver and kidneys to help diuretic and lower the intestinal fever has the effect of preventing constipation.
감초(甘草, Glycyrrhiza uralensis FISCH.)는 콩과의 다년생 초본으로, 감초는 한방에서 모든 약재와 조화를 이루면서 효능을 증가시킬 뿐만 아니라 완화, 진통약으로 각종 동통 및 급박증상을 완화하는데 내복용 또는 외용으로 사용되고, 그 자체가 독의 중화작용과 같은 약성이 있다. 예를 들면, 감초는 간장을 보호하고 간기능을 원활하게 하여 피로를 조절하는 약효가 있어서, 감초를 복용하면 그 해독작용에 의해 간의 부담이 경감된다. 식물의 뿌리 및 근경에 트리터펜(triterpene)계 사포닌(saponin), 글리시리진(glycyrrhizin)이 함유되어 있어 약물 중독, 음식물 중독, 체내대사물의 중독뿐 만 아니라 세균독소에 대한 모든 해독작용을 가지며, 항이뇨작용 및 갑상선피지호르몬양의 조절 작용이 있다. 감초는 항염증과 항알레르기반응작용을 보이며, 아세틸콜린에 대해 길항하는 작용을 나타내며, 아드레날린의 강심작용을 증강시키는 효과가 있다.Licorice (Glycyrrhiza uralensis FISCH.) Is a perennial herb, which is a herbaceous perennial herb, which not only increases its efficacy in harmony with all herbs in oriental medicine, but also alleviates various pain and urgency as an alleviation and analgesic medicine. It is used as a drug, and itself has a weakness such as neutralization of poison. For example, licorice has the effect of protecting the liver and smoothing the liver and regulating fatigue, and taking licorice reduces the burden on the liver by its detoxification. Triterpene-based saponins and glycyrrhizin are contained in the roots and roots of plants, which have all the detoxifying effects on bacterial toxins as well as drug addiction, food poisoning, and metabolism in the body. There is a function and regulation of thyroid sebum hormone. Licorice has anti-inflammatory and anti-allergic reactions, antagonistic action against acetylcholine, and has the effect of enhancing the cardiac action of adrenaline.
박하(Mentha arvensis var. piperascens)는 꿀풀과의 다년생 초본으로, 식물자체에 방향성을 가지고 있고 직립하여 상부에서 분지되어있다. 이 박하추출물에는 멘톨, 이소멘톤, 피넨, 캄펜, 리모넨, 진게론, 쇼가올 등의 유효성분을 함유하여 청량하면서도 산뜻한 향을 발산하고, 피부나 두피에 존재하는 습진, 옴 등을 일으키는 병원성 진균, 대장균 포도상구균 등의 미생물에 대해서 살균 및 항균작용을 갖는다. 특히 비듬과 가려움증을 악화시키는 주요 원인인 피티로스포름 오발레(Pityrosporum Ovale)라는 미생물의 증식 및 활성 중대를 억제할 수 있고, 자극, 홍반 및 지루성 염증을 완화하는 효과가 있다 (대한민국 등록특허 제448,434호).Mint (Mentha arvensis var. Piperascens) is a perennial herb of Lamiaceae, which has a fragrance to the plant itself and is upright and branched from the top. This peppermint extract contains active ingredients such as menthol, isomentone, pinene, camphor, limonene, gingeron and shogaol, and emits a refreshing and fresh scent, and pathogenic fungi that cause eczema and scabies on the skin or scalp. It has bactericidal and antimicrobial activity against microorganisms such as Escherichia coli and Staphylococcus aureus. In particular, it can inhibit the growth and activity of microorganisms called Pyrosporum Ovale, which is a major cause of worsening dandruff and itching, and has an effect of alleviating irritation, erythema and seborrheic inflammation (Korean Patent No. 448,434 number).
엿기름(맥아)는 식혜,맥주,고추장,위스키등을 만들 때 사용하는 것으로 보리를 발아시킨다음 일정시간이 지나서 발아의 진행을 중단시킨것으로 현재 시장에서 쉽게 구할 수 있는 재료로 가정에서도 일반 사람들이 쉽게 식혜.고추장 등의 음식을 만들 때 상용하고 있다. 엿기름은 몸속에서 나쁜 것을 제거하고 소화를 촉진하며 근육과 뼈를 튼튼히 하고 천연소염제와 방부제 역할을 한다.Malt (malt) is used to make Sikhye, beer, red pepper, whiskey, etc. It germinates barley and stops the germination after a certain period of time. It is commonly used to make food such as Sikhye and red pepper paste. Malt removes bad things from the body, promotes digestion, strengthens muscles and bones, and acts as a natural anti-inflammatory and preservative.
쌀은 필수아미노산을 다량 함유하고 있으며 또한 쌀눈에는 쌀의 영양소가 66%가 함유되어 있으며, 쌀눈 속에는 중금속을 해독시키는 피틴산(phytic acid)이 백미에 비해 6배나 들어있고, 단백질, 지방, 탄수화물이 풍부하고, 섬유질과 비타민 A, 비타민 B1, B2, B6, 비타민 E, 판토테인산(panthothenic acid), 리놀레산 (linoleic acid) 등의 비타민과 미네랄이 균형을 유지하며, 항암인자를 억제하는 킬레이트 물질도 포함한다고 알려져 있다. 또한, 쌀눈에는 토코페롤보다 항산화작용이 강한 토코트리에놀(tocotrienol), 뇌세포의 활동을 활발하게 하여 뇌졸중과 치매를 예방하는 오리자놀 등이 포함되어 있다. 또한, 섬유질이 풍부하여 수분의 함량을 높여 변비를 예방하고, 인슐린 분비를 늦춰 당뇨 예방에도 효과가 있다고 알려져 있다. 또한 쌀의 철분, 칼슘, 마그네슘, 나트륨,비타민E 등의 성분이 인체의 항상성을 유지시켜주고 토크페롤 등의 노화방지 주름살 및 기미, 주근깨, 여드름, 아토피진정 효과에 탁월한 효과가 있었음이 밝혀졌다. Rice contains a large amount of essential amino acids, and the rice eye contains 66% of the nutrients of rice. The rice snow contains six times as much phytic acid as detoxifying heavy metals, and is rich in protein, fat, and carbohydrates. In addition, fiber and vitamins such as vitamin A, vitamins B1, B2, B6, vitamin E, panthothenic acid and linoleic acid are in balance, and chelate substances that inhibit anticancer factors are also included. It is known. In addition, rice eyes include tocotrienol, which is stronger in antioxidant activity than tocopherol, oryzanol, which prevents stroke and dementia by activating the activity of brain cells. In addition, it is known that the fiber is rich in moisture to prevent constipation by increasing the content of moisture, and slows down the secretion of insulin to prevent diabetes. In addition, the iron, calcium, magnesium, sodium, vitamin E, etc. of the rice to maintain the homeostasis of the human body was found to have an excellent effect on the anti-aging wrinkles and blemishes, freckles, acne, atopy soothing effects such as torque perol.
율무는 자양강장, 이뇨, 배농, 혈압강화, 배란촉진, 면역기능강화, 항종양 및 진통 등에 생리활성 효과가 있다고 알려져 있다. 율무는 로이신, 글루타민산, 발린티로산, 프로린 등의 아미노산이 많이 함유되어 있고 율무쌀은 자양강장의 효과가 있으며 이뇨와 미용에도 좋은 것으로 알려져 있다. 본초강목에는 율무가 위에 좋으며, 비장을 튼튼히 하고, 폐를 보한다고 기재되어 있다. 그 밖에 열과 풍을 없애주며, 습(濕)을 이기게 한다고 기재되어 있다.Yulmu is known to have physiological activities such as nourishing tonic, diuresis, drainage, blood pressure, ovulation, immune function, anti-tumor and analgesic. Yulmu is rich in amino acids such as leucine, glutamic acid, valintyroic acid, and proline. Yulmu rice is known to be effective for nourishing tonic and diuretic and beauty. Herbal wood is said to have good yulmu, stomach strengthening, spleen, lungs. In addition, it is said to remove heat and wind, and to overcome humidity.
동백나무(Camellia Japonica)는 상록활엽수 교목으로, 휜 줄기에서 잔가지가 많이 나와 장 타원형 또는 반 구형의 수형을 이루며, 수피는 회백색으로 평활하고, 잎은 어긋나고 타원형 또는 긴 타원형으로 잔 톱니가 길이 5~12cm, 넓이 3~7cm로 표면은 짙은 녹색이다.Camellia Japonica is an evergreen broad-leaved arboreous tree, with many twigs on the stem of 휜, long oval or semi-spherical, with bark smooth gray, leaves alternate, oval or long oval, and sawtooth 5 ~ It is 12cm wide and 3-7cm wide, and the surface is dark green.
동백속의 성분 분석 및 활용화에 관해 많은 연구가 진행되어 동백유와 유박의 급성 테스트를 통해 안전성을 확인하였으며, 유박에 함유된 성분이 알코올 흡수 저해효과가 있다고 보고된 바 있으며, 종실에서 분리한 하이퍼로사이드(hyperoside)는 AIDS 유발과 관련된 HIV-1 프로테아제(HIV-1 protease)에 대하여 억제효과를 보였고, 씨와 과피의 추출물도 항염 및 소염활성, 줄기의 메탄올 추출물은 지질과 산화를 억제하는 것으로 나타났다. 또한 동백꽃에는 프로라인과 글루타민 산을 주된 아미노산으로 존재하고 있고 기타 미량의 유리 아미노산이 존재하는 것으로 나타났다.
Numerous studies have been conducted on the analysis and utilization of components of camellia to confirm the safety through acute tests of camellia oil and oil foil. It has been reported that the components contained in oil have an inhibitory effect on alcohol absorption. Hypersides showed inhibitory effects on HIV-1 protease associated with AIDS induction. Seed and rind extracts also showed anti-inflammatory and anti-inflammatory activity, while methanol extracts on stems inhibited lipid and oxidation. . It was also found that camellia has proline and glutamic acid as the main amino acids and other trace free amino acids.
본 발명은 상기와 같은 점들을 감안하여 예의 연구를 진행한 결과 안출한 것으로, 특히 모세혈관을 원활하게 하는 효과를 갖는 여러 천연물질을 자연발효시켜 제조한 혈액순환 개선용 식품 조성물 및 이의 제조방법을 제공하는데 그 목적이 있다. The present invention has been made in view of the above points as a result of a thorough research, in particular a food composition for improving blood circulation prepared by natural fermentation of various natural substances having the effect of smoothing capillaries and a method for producing the same The purpose is to provide.
본 발명의 상기 목적은 천연물질인 아마씨, 메밀, 약쑥, 은행잎, 솔잎, 결명자, 감초, 박하, 엿기름, 쌀, 율무, 동백, 흑설탕 및 알콜을 자연발효시키고 여과시켜 식품 조성물을 제조하고, 상기 화장료 조성물의 주름 및 잡티 개선 효과를 평가함으로써 달성하였다.The object of the present invention is to natural foods flaxseed, buckwheat, wormwood, ginkgo biloba, pine needles, crystallization, licorice, peppermint, malt, rice, barley, camellia, brown sugar, and alcohol to ferment and filter to prepare a food composition, the cosmetics Achieved by evaluating the effect of improving the wrinkles and blemishes of the composition.
본 발명의 천연물질을 사용하여 제조한 식품 조성물은 모세혈관의 혈액순환을 원활하게 하여 고혈압, 당뇨병, 비만 등의 혈액순환 장애 관련 질환의 예방 및 치료에 뛰어난 효과가 있다.The food composition prepared using the natural material of the present invention has an excellent effect on the prevention and treatment of diseases related to blood circulation disorders such as hypertension, diabetes, obesity by smoothing the blood circulation of capillaries.
본 발명은 아마씨, 메밀, 약쑥, 은행잎, 솔잎, 결명자, 감초, 박하, 엿기름, 쌀, 율무, 동백, 흑설탕 및 알콜을 자연발효시켜 제조한 식품 조성물 및 그 제조방법에 관한 것이다. The present invention relates to a food composition prepared by natural fermentation of flaxseed, buckwheat, wormwood, ginkgo biloba, pine needles, crystals, licorice, peppermint, malt, rice, barley, camellia, brown sugar and alcohol, and a method for producing the same.
흑설탕은 상기 천연물질들을 자연발효시키는 미생물의 영양원으로 공급된 것이며, 흑설탕 이외에 백설탕, 황설탕, 포도당 등 본 분야에서 발효 미생물 영양원으로 사용되는 모든 영양원을 사용할 수 있다. 알콜은 자연발효시 유해미생물 또는 곰팡이의 발생을 억제하고 방부작용을 위해 첨가하였다.Brown sugar is supplied as a nutrient source of microorganisms that naturally ferment the natural substances, and in addition to brown sugar, any nutrient source used as fermentation microorganism nutrient source in the field such as white sugar, yellow sugar, and glucose may be used. Alcohol was added for antiseptic action and to prevent the occurrence of harmful microorganisms or mold during natural fermentation.
본 발명의 조성물은 모세혈관의 혈액순환을 촉진하므로, 혈액순환에 문제가 있어 발생하는 여러 증상의 개선에 효과적이다.
Since the composition of the present invention promotes blood circulation of capillaries, it is effective in improving various symptoms caused by problems in blood circulation.
아토피 증상으로 인한 가려움증 또는 피부 트러블과 같은 식생활로 인한 피부 질환을 완화시키는데 효과적이다.It is effective in relieving skin diseases caused by diet, such as itching or skin problems caused by atopic symptoms.
또한 과식으로 인한 소화불량, 위산과다로 인한 속쓰림 발생시에 본 발명의 조성물을 섭취하면 속쓰림 및 소화불량 증상이 개선된다.In addition, ingestion of the present invention at the time of heartburn due to indigestion due to overeating, excessive stomach acid, heartburn and indigestion symptoms are improved.
전립선비대증 또는 전립선 염증으로 인한 배뇨곤란, 빈뇨 등의 증상을 예방하거나 완화시킬 수 있다.It can prevent or alleviate symptoms such as dyspnea and frequent urination caused by prostatic hyperplasia or inflammation of the prostate gland.
혈액순환 장애로 인한 다리, 손, 발, 얼굴, 눈 등의 부종에도 효과적이다.It is also effective for swelling of the legs, hands, feet, face and eyes due to blood circulation disorders.
고혈압, 당뇨병, 동맥경화증, 심장병, 뇌졸중과 같은 혈액순환 장애의 예방 또는 완화에 효과적이다.
It is effective in preventing or alleviating blood circulation disorders such as high blood pressure, diabetes, arteriosclerosis, heart disease and stroke.
본 발명의 조성물은 식품 조성물로서 음료, 엑기스, 겔, 캡슐, 정제, 환약, 분말 등의 형태로 제조할 수 있다.The composition of the present invention can be prepared in the form of beverages, extracts, gels, capsules, tablets, pills, powders, and the like.
본 발명의 조성물은 맛을 개선하거나 필요한 형상으로 만들기 위해서 담체 또는 첨가제를 선택적으로 포함하는 제형으로 제조할 수 있다. 상기 담체 또는 첨가제는 희석제, 감미제, 안정제, 향료, 비타민류, 항산화제 등이 있다. The compositions of the present invention may be prepared in formulations that optionally include a carrier or additive to improve taste or to shape into the required shape. The carrier or additive includes diluents, sweeteners, stabilizers, flavoring agents, vitamins, antioxidants and the like.
상기 담체 또는 첨가제는 약학적으로 용인 가능한 것은 모두 가능하며, 예를 들어 희석제는 유당, 곡물 전분 등이 있으며, 감미제로는 설탕, 액상과당, 결정과당, 슈크랄로스, 솔비톨 또는 아스파탐이 있고 안정제로는 카르복시메틸셀룰로스나트륨, 베타-사이클로덱스트린 또는 잔탄검 등이 있다. 또한 조성물의 미각을 개선시키기 위해 과일향, 허브향 등의 천연향료, 천연과즙, 플라보노이드 등의 천연색소, 과당, 벌꿀, 설탕과 같은 감미성분 또는 구연산, 구연산나트륨과 같은 산미제를 추가로 포함할 수 있다. 또한, 본 발명의 조성물은 유효성분 이외에 보조성분으로서 비타민 B, C, E 또는 베타카로틴, Ca, Mg, Zn 등의 무기질 성분 또는 레시틴 등의 인지질 성분, 또는 올리고당, 아미노산, 타우린 등을 추가로 포함할 수 있다.
The carrier or additive may be any pharmaceutically acceptable, for example, diluents include lactose, grain starch, etc., and sweeteners include sugar, liquid fructose, crystalline fructose, sucralose, sorbitol or aspartame and stabilizers. Sodium carboxymethylcellulose, beta-cyclodextrin or xanthan gum. In addition, in order to improve the taste of the composition, natural flavors such as fruit and herb flavors, natural pigments such as natural fruit juices and flavonoids, sweeteners such as fructose, honey and sugar or acidic agents such as citric acid and sodium citrate Can be. In addition to the active ingredient, the composition of the present invention further contains an inorganic component such as vitamin B, C, E or beta-carotene, Ca, Mg, Zn or phospholipid components such as lecithin, or oligosaccharides, amino acids, taurine, etc. as an auxiliary component. can do.
실시예Example 1. 본 발명의 식품 조성물의 제조 1. Preparation of the food composition of the present invention
각각 1중량부의 아마씨, 메밀, 약쑥, 은행잎, 솔잎, 결명자, 감초, 박하, 엿기름, 쌀, 율무 및 동백잎과 줄기를 혼합한 후, 여기에 총 중량의 5 중량%의 흑설탕 및 10 중량%의 알콜을 첨가한 후 밀봉하고 암실에서 15℃ 내지 20℃에서 15일간 자연발효시켰다. 15일 후에 개봉하여 발효액을 광목, 거즈 등의 여과천으로 여과하여 노란색의 발효물을 수득하였다.
After mixing 1 part by weight of flaxseed, buckwheat, wormwood, ginkgo biloba, pine needles, cranberry, licorice, peppermint, malt, rice, pearl radish and camellia leaf and stalk, respectively, 5% by weight of brown sugar and 10% by weight of After the addition of the alcohol was sealed and spontaneously fermented at 15 ° C. to 20 ° C. for 15 days in the dark. After 15 days, the mixture was opened and the fermentation broth was filtered through a filter cloth such as mineral or gauze to obtain a yellow fermented product.
실험예Experimental Example 1 : 동맥경화 억제효과 측정 1: Measurement of arteriosclerosis inhibitory effect
실험동물로는 체중 20?25g 내외의 스프라그-돌리(Sprague-Dawley) 랫을 10마리씩 두 군으로 나누어 정상군에는 올리브유만을, 대조군 및 실험군에는 콜레스테롤 40m/㎏과 콜레칼시페롤 3200 IU/㎏을 올리브유에 용해시켜 28일 동안 1일 1회 경구투여하여 동맥경화증을 유발시켰다. 실험군에는 본 발명의 조성물을 각각 0.250 g/㎏의 농도로 7일 동안 1일 1회 경구투여하고, 정상군과 대조군에는 동량의 생리식염수를 동일한 방법으로 경구투여하였다. 실험 최종일에 정상군, 대조군 및 실험군을 12시간동안 절식시킨 후 우레탄마취시켜서 복대동맥으로부터 채혈하였다. 얻은 혈액을 3000rpm 하에서 15분간 원심분리하여 용혈되지 않은 혈청을 채취한 다음, 효소법에 의하여 총 콜레스테롤의 함량, 총 콜레스테롤 중에 함유된 HDL-콜레스테롤의 함량을 측정하였으며, 혈청 중의 트리글리세라이드의 함량과 칼슘함량은 각각 측정용 키트(kit)를 사용하여 측정하였다. 실험결과는 표 2에 나타낸 바와 같다.
The experimental animals were divided into two groups of 10 Sprague-Dawley rats, each weighing about 20 to 25 g, divided into two groups. Only olive oil was used in the normal group, 40 m / kg cholesterol and 3200 IU / kg cholecalciferol in the control group and the experimental group. Was dissolved in olive oil orally administered once a day for 28 days to induce atherosclerosis. In the experimental group, the composition of the present invention was orally administered once daily for 7 days at a concentration of 0.250 g / kg, and the same amount of normal saline was orally administered to the normal group and the control group. On the last day of the experiment, the normal, control and experimental groups were fasted for 12 hours, and urine was anesthetized and blood was collected from the abdominal aorta. The obtained blood was centrifuged at 3000 rpm for 15 minutes to collect unhemolyzed serum, and then the total cholesterol content and the HDL-cholesterol content in total cholesterol were measured by enzymatic method. Were each measured using a kit for measurement. The experimental results are shown in Table 2.
실험예Experimental Example 2. 본 발명의 식품 조성물의 관능평가 2. Sensory evaluation of the food composition of the present invention
실시예 1에서와 같이 제조한 본 발명의 조성물의 관능평가를 15명의 성인을 대상으로 실시하였다. 관능평가는 10점 척도법을 사용하여 매우 좋지 않음(1점), 보통(5점), 매우 좋음(10점)으로 평가하였다. 결과는 표 1과 같다.
Sensory evaluation of the composition of the present invention prepared as in Example 1 was carried out for 15 adults. Sensory evaluation was evaluated as very poor (1 point), moderate (5 points), and very good (10 points) using the 10-point scale method. The results are shown in Table 1.
본 발명의 조성물은 맛, 식감, 기호도 부분에서 평균 9.0 이상의 응답 결과를 보여 본 발명의 식품 조성물의 음용성이 좋음을 확인할 수 있었다. The composition of the present invention showed an average of 9.0 or more response results in taste, texture, preference, it was confirmed that the food composition of the present invention is good drinking.
Claims (3)
상기 혼합물 총 중량의 5 중량%의 흑설탕 및 10 중량%의 알콜을 첨가한 후 밀봉하는 단계;
암실에서 15℃ 내지 20℃에서 15일간 자연발효시키는 단계; 및
15일 후에 개봉하여 발효액을 여과하는 단계
를 포함하는 혈액순환 개선용 조성물의 제조방법.Mixing flaxseed, buckwheat, wormwood, ginkgo biloba, pine needles, bladder, licorice, peppermint, malt, rice, barley and camellia with stem;
Adding 5 weight percent brown sugar and 10 weight percent alcohol to the total weight of the mixture and then sealing;
Spontaneous fermentation at 15 ℃ to 20 ℃ 15 days in the dark; And
Opening after 15 days to filter the fermentation broth
Method for producing a composition for improving blood circulation comprising a.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020100087432A KR101227063B1 (en) | 2010-09-07 | 2010-09-07 | Food composition for improving circulation of blood and manufacturing method thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020100087432A KR101227063B1 (en) | 2010-09-07 | 2010-09-07 | Food composition for improving circulation of blood and manufacturing method thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20120025197A true KR20120025197A (en) | 2012-03-15 |
KR101227063B1 KR101227063B1 (en) | 2013-01-29 |
Family
ID=46131667
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020100087432A KR101227063B1 (en) | 2010-09-07 | 2010-09-07 | Food composition for improving circulation of blood and manufacturing method thereof |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR101227063B1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20160084915A (en) * | 2015-01-06 | 2016-07-15 | 목포대학교산학협력단 | Composition comprising the extract of Camellia japonica for prevention and treatment of cardiovascular diseases |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101315005B1 (en) | 2013-07-18 | 2013-10-04 | 이정숙 | Method for manufacturing grain syrup using ginkgo leaves |
KR102466832B1 (en) | 2020-09-18 | 2022-11-15 | 천지인초 주식회사 | Functional food composition having cranial nerve protection effect and blood flow improvement effect |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR920019343A (en) * | 1991-04-10 | 1992-11-19 | 이순목 | Composition for preventing and treating vascular disease using α-linolenic acid |
KR20020003165A (en) * | 2001-11-23 | 2002-01-10 | 송윤강 | Process for Producing a fermented food for health aid |
KR20030004993A (en) * | 2002-03-29 | 2003-01-15 | 김용문 | Method for manufacturing complex health fermented food on the base natural plant |
-
2010
- 2010-09-07 KR KR1020100087432A patent/KR101227063B1/en active IP Right Grant
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20160084915A (en) * | 2015-01-06 | 2016-07-15 | 목포대학교산학협력단 | Composition comprising the extract of Camellia japonica for prevention and treatment of cardiovascular diseases |
Also Published As
Publication number | Publication date |
---|---|
KR101227063B1 (en) | 2013-01-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6077554B2 (en) | Wrapping fermentation method using medicinal flowers and skin external preparation composition using the method | |
CN101120787B (en) | Granada health-care beverage and its preparation method | |
CN101181058B (en) | Five-element fruit vegetables nutrition preparations for reinforcing human body five-organs function and preparation method thereof | |
KR20160087114A (en) | Food additive containing flowers | |
KR20160087113A (en) | Cosmetics containing flowers | |
KR20160087112A (en) | Flower tea and method for manufacturing therof | |
CN108719724A (en) | Collagen solid beverage and preparation method thereof | |
KR101855421B1 (en) | Agricultural products with a pharmacological action and the mycelium mixtures are fermented food composition method of preparing the same | |
CN106070626A (en) | Fermented mare milk fruit beverage and preparation method thereof | |
KR20090127970A (en) | Uncooked food pill and its manufacturing process | |
CN102823654A (en) | Series Chinese medicine health-care milk tablet and preparation method thereof | |
CN102940219B (en) | Potato cake and making method thereof | |
KR101227063B1 (en) | Food composition for improving circulation of blood and manufacturing method thereof | |
KR20210063657A (en) | A natural tea removing the effect of hangover contained the extract material in Hovenia dulcis and a cactus | |
CN105532991A (en) | Composite dark green tea with functions of maintaining beauty and caring skin and preparation method thereof | |
KR101163069B1 (en) | Cosmetic composition for anti-blemish and anti-wrinkle and method for manufacturing thereof | |
CN104255883A (en) | Health protection cake capable of adjusting blood glucose and blood fat and production method thereof | |
KR101999675B1 (en) | Herbal composition for the prevention and treatment of coronary heart disease | |
KR20200107444A (en) | The skin cosmetic composition for anti-oxidation and anti-wrinkle of skin comprising natural complex extracts | |
CN105981853A (en) | Nutritional function enriched mild warm tea drink recipe | |
KR101053064B1 (en) | Supplements for skin improvement using edible snails, eel bone and herbal medicine | |
KR101723962B1 (en) | Atopic dermatitis mitigate functional composition using environmentally friendly natural ingredients | |
Shah et al. | Fruit and fruit products as functional foods | |
CN110679935A (en) | Burdock and ginseng essence cream and preparation method thereof | |
KR20230003840A (en) | Fermented low molecular collagen of using complex enzyme and its manufacturing method |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20151204 Year of fee payment: 4 |
|
FPAY | Annual fee payment |
Payment date: 20170209 Year of fee payment: 5 |
|
FPAY | Annual fee payment |
Payment date: 20171219 Year of fee payment: 6 |
|
FPAY | Annual fee payment |
Payment date: 20181226 Year of fee payment: 7 |
|
FPAY | Annual fee payment |
Payment date: 20200109 Year of fee payment: 8 |